Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Coloplast A/S
  6. Summary
    COLO B   DK0060448595

COLOPLAST A/S

(COLO B)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Copenhagen
05/19/2022 05/20/2022 05/23/2022 05/24/2022 05/25/2022 Date
837.8(c) 853.4(c) 826.6(c) 796.6(c) 801.6(c) Last
327 509 311 999 310 011 371 917 371 794 Volume
-2.81% +1.86% -3.14% -3.63% +0.63% Change
More quotes
Estimated financial data (e)
Sales 2022 22 081 M 3 180 M 3 180 M
Net income 2022 4 880 M 703 M 703 M
Net Debt 2022 17 661 M 2 543 M 2 543 M
P/E ratio 2022 34,7x
Yield 2022 2,23%
Sales 2023 24 467 M 3 523 M 3 523 M
Net income 2023 5 781 M 832 M 832 M
Net Debt 2023 15 159 M 2 183 M 2 183 M
P/E ratio 2023 29,4x
Yield 2023 2,54%
Capitalization 170 B 24 508 M 24 508 M
EV / Sales 2022 8,51x
EV / Sales 2023 7,58x
Nbr of Employees 14 286
Free-Float 57,3%
More Financials
Company
Coloplast A/S specializes in the design, manufacturing, and marketing of disposable medical products. Net sales break down by family of products as follows: - hygiene products (76.4%): urine bags, plugs, urinary testing systems and sets, etc.; - wound care and skincare products (12.8%): wound dressings, bandages, creams and gels ; - ostomy care products (10.8%): bags and equipment used following intestinal... 
Read more
More about the company
Ratings of Coloplast A/S
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about COLOPLAST A/S
05/17New informational website around larynx cancer surgery
GL
05/17New informational website around larynx cancer surgery
GL
05/11Announcement no. 06/2022 - Coloplast announces the successful issuance of EUR 2.2 billi..
GL
05/09Announcement no. 05/2022 - Coloplast announces the establishment of its Euro Medium Ter..
GL
05/09Announcement no. 05/2022 - Coloplast announces the establishment of its Euro Medium Ter..
GL
05/09COLOPLAST A/S : Ex-dividend day for interim dividend
FA
05/06S&P Assigns Stable Outlook To Danish Medical Technology Group Coloplast
MT
05/05GLOBAL MARKETS LIVE : BAE, Shell, Berkshire Hathaway, Nissan, Shopify...
05/05TRANSCRIPT : Coloplast A/S, H1 2022 Earnings Call, May 05, 2022
CI
05/05The Board of Directors of Coloplast A/S Approves A Half Year Interim Dividend of DKK 5 ..
CI
05/05Coloplast Shares Down as Fiscal H1 Profit Slips; Revenue Grows
MT
05/05Coloplast delivers a solid Q2 with 7% organic growth and a 31% EBIT margin and revises ..
GL
05/05Coloplast delivers a solid Q2 with 7% organic growth and a 31% EBIT margin and revises ..
GL
05/05Coloplast A/S Provides Earnings Guidance for the Full Year of 2022
CI
05/05Coloplast A/S - Announcement no. 04/2022 – Interim Financial Report, H1 2021/22
GL
More news
News in other languages on COLOPLAST A/S
05/17Nouveau site internet d'informations sur la chirurgie du cancer du larynx
05/17Nueva web informative sobre la cirugía del cancer de laringe
05/06S&P attribue une perspective stable au groupe danois de technologie médicale Coloplast
05/05Le conseil d'administration de Coloplast A/S approuve un dividende intérimaire semestri..
05/05Les actions de Coloplast en baisse suite à la chute du bénéfice du premier semestre fis..
More news
Analyst Recommendations on COLOPLAST A/S
More recommendations
Chart COLOPLAST A/S
Duration : Period :
Coloplast A/S Technical Analysis Chart | COLO B | DK0060448595 | MarketScreener
Technical analysis trends COLOPLAST A/S
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 801,60 DKK
Average target price 1 051,33 DKK
Spread / Average Target 31,2%
EPS Revisions
Managers and Directors
Kristian Villumsen President & Chief Executive Officer
Anders Lonning-Skovgaard Chief Financial Officer & Executive Vice President
Lars Søren Rasmussen Chairman
Oliver Johansen Senior VP-Global Research & Development
Allan Rasmussen Executive Vice President-Global Operations
Sector and Competitors
1st jan.Capi. (M$)
COLOPLAST A/S-30.36%24 508
SHANDONG WEIGAO GROUP MEDICAL POLYMER COMPANY LIMITED-16.96%4 705
HARTALEGA HOLDINGS BERHAD-27.75%3 231
TOP GLOVE CORPORATION BHD.-45.95%2 560
INTCO MEDICAL TECHNOLOGY CO., LTD.-52.90%2 235
SHANDONG PHARMACEUTICAL GLASS CO., LTD-47.27%2 056